Although EGFR/RB1/TP53 triple mutation seems to identify a group of patients at the highest risk for SCLC transformation, biomarkers to predict transformation to SCC, EMT, and LCNEC are currently lacking. This evidence concerns the gene RB1 and small cell lung carcinoma.